Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

ClinicalTrials.gov ID: NCT02282020

Public ClinicalTrials.gov record NCT02282020. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 21, 2026, 10:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physician's Choice Single Agent Chemotherapy in the Treatment of Platinum Sensitive Relapsed Ovarian Cancer in Patients Carrying Germline BRCA1/2 Mutations.

Study identification

NCT ID: NCT02282020
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: AstraZeneca; Industry
Enrollment: 266 participants

Conditions and interventions

Conditions

Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity

Interventions

OLAPARIB Drug
Single agent chemotherapy Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 130 Years
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 5, 2015
Primary completion: Oct 9, 2018
Completion: Jul 18, 2022
Last update posted: Jul 25, 2022

2015 – 2022

United States locations

U.S. sites: 22
U.S. states: 16
U.S. cities: 22

Facility	City	State	ZIP	Site status
Research Site	Birmingham	Alabama	35233	—
Research Site	Mobile	Alabama	36604	—
Research Site	Sacramento	California	95817	—
Research Site	San Francisco	California	94118	—
Research Site	Aurora	Colorado	80045	—
Research Site	Littleton	Colorado	80120	—
Research Site	Hartford	Connecticut	06106	—
Research Site	Fort Gordon	Georgia	30905	—
Research Site	Covington	Louisiana	70433	—
Research Site	Towson	Maryland	21204	—
Research Site	Detroit	Michigan	48201	—
Research Site	Albany	New York	12208	—
Research Site	Mineola	New York	11501	—
Research Site	Chapel Hill	North Carolina	27599	—
Research Site	Columbus	Ohio	43210	—
Research Site	Springfield	Oregon	97477	—
Research Site	Abington	Pennsylvania	19001	—
Research Site	Knoxville	Tennessee	37920	—
Research Site	Nashville	Tennessee	37232	—
Research Site	Bedford	Texas	76022	—
Research Site	Houston	Texas	77030	—
Research Site	Milwaukee	Wisconsin	53226	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 72 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02282020, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 25, 2022 · Synced Jul 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02282020 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →